Literature DB >> 18332424

Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome.

Soong Ho Kim1, Julie A Markham, Ivan Jeanne Weiler, William T Greenough.   

Abstract

Fragile X syndrome (FXS) has so far resisted efforts to define the basic cellular defects caused by the absence of a single protein, fragile X mental retardation protein (FMRP), because the patients have a wide variety of symptoms of varying severity. Immature-appearing dendritic spines on neurons found in FXS patients and fmr1-KO mice suggest a role for FMRP in modulating production of synaptic structural proteins. We isolated cortical synaptoneurosomes from WT and KO mice and studied MAPK pathway activation after group I metabotropic glutamate receptor (mGluR) stimulation. Here, we show that ERK in KO synaptoneurosomes is rapidly dephosphorylated upon mGluR1/5 stimulation, whereas it is phosphorylated in WT mice, suggesting that aberrant activation of phosphatases occurs in KO synapses in response to synaptic stimulation. In KO synapses, protein phosphatase 2A (PP2A) is overactivated after mGluR1 stimulation, and tyrosine phosphatase is overactivated after mGluR5 stimulation, causing the rapid deactivation of ERK. ERK activation can be restored in KO by pretreatment with phosphatase blockers; blocking of PP2A by okadaic acid could successfully restore normal ERK activation in KO synaptoneurosomes. We propose that overactivation of phosphatases in synapses may be a key deficit in FXS, which affects synaptic translation, transcription, and synaptic receptor regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332424      PMCID: PMC2393788          DOI: 10.1073/pnas.0800257105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations.

Authors:  Ornella Valenti; P Jeffrey Conn; Michael J Marino
Journal:  J Cell Physiol       Date:  2002-05       Impact factor: 6.384

Review 2.  Dendritic spine pathology: cause or consequence of neurological disorders?

Authors:  John C Fiala; Josef Spacek; Kristen M Harris
Journal:  Brain Res Brain Res Rev       Date:  2002-06

3.  Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.

Authors:  V Brown; P Jin; S Ceman; J C Darnell; W T O'Donnell; S A Tenenbaum; X Jin; Y Feng; K D Wilkinson; J D Keene; R B Darnell; S T Warren
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

4.  Altered synaptic plasticity in a mouse model of fragile X mental retardation.

Authors:  Kimberly M Huber; Sean M Gallagher; Stephen T Warren; Mark F Bear
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  The fragile X mental retardation protein inhibits translation via interacting with mRNA.

Authors:  Z Li; Y Zhang; L Ku; K D Wilkinson; S T Warren; Y Feng
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

6.  Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function.

Authors:  G Mannaioni; M J Marino; O Valenti; S F Traynelis; P J Conn
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

7.  Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex.

Authors:  S Ceman; V Brown; S T Warren
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

8.  Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency.

Authors:  Jianxue Li; Marc R Pelletier; Jose-Luis Perez Velazquez; Peter L Carlen
Journal:  Mol Cell Neurosci       Date:  2002-02       Impact factor: 4.314

9.  PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress.

Authors:  Lourdes Garcia; Fatima Garcia; Franc Llorens; Mercedes Unzeta; Emilio Itarte; Néstor Gómez
Journal:  FEBS Lett       Date:  2002-07-17       Impact factor: 4.124

10.  Phosphorylation of Ser166 in RGS5 by protein kinase C causes loss of RGS function.

Authors:  Kayoko Moroi; Mariko Nishiyama; Shin-ichirou Kawabata; Hideaki Ichiba; Takehiko Yajima; Sadao Kimura
Journal:  Life Sci       Date:  2007-05-01       Impact factor: 5.037

View more
  48 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 2.  Taking STEPs forward to understand fragile X syndrome.

Authors:  Susan M Goebel-Goody; Paul J Lombroso
Journal:  Results Probl Cell Differ       Date:  2012

Review 3.  Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Authors:  Dilja D Krueger; Mark F Bear
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 4.  The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Mol Neurobiol       Date:  2009-02-12       Impact factor: 5.590

Review 5.  Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Authors:  Kyle C Wilcox; Pascale N Lacor; Jason Pitt; William L Klein
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

Review 6.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

7.  Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain.

Authors:  Tara C Tassin; David R Benavides; Florian Plattner; Akinori Nishi; James A Bibb
Journal:  J Biol Chem       Date:  2015-05-13       Impact factor: 5.157

8.  Determination of dendritic spine morphology by the striatin scaffold protein STRN4 through interaction with the phosphatase PP2A.

Authors:  Lianfeng Lin; Louisa Hoi-Ying Lo; Quanwei Lyu; Kwok-On Lai
Journal:  J Biol Chem       Date:  2017-04-25       Impact factor: 5.157

9.  Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases.

Authors:  Agata Gozdz; Aruna Vashishta; Katarzyna Kalita; Erzsebet Szatmari; Jing-Juan Zheng; Shigeo Tamiya; Nicholas A Delamere; Michal Hetman
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

10.  Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.

Authors:  Hailan Hu; Yi Qin; Genrieta Bochorishvili; Yinghua Zhu; Linda van Aelst; J Julius Zhu
Journal:  J Neurosci       Date:  2008-07-30       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.